Summary: Researchers have shown that a targeted antioxidant therapy can overcome the neurodevelopmental deficits associated with 22q11.2 deletion syndrome by engaging alternative cellular pathways, without repairing the underlying chromosomal deletion.
Using a validated mouse model of 22q11.2 deletion syndrome — the second most common chromosomal microdeletion in humans and a major genetic risk factor for schizophrenia and autism spectrum disorder — the team identified mitochondrial oxidative stress as a central cause of abnormal dendritic growth and weakened synaptic connectivity.
Treatment with the antioxidant N‑acetyl cysteine (NAC), which penetrates the blood-brain barrier, reduced oxidative stress, improved mitochondrial function, and restored dendritic arborization. Importantly, NAC did not reinstate the original expression of the deleted genes. Instead, it triggered an alternative network of compensatory genes that enabled neurons to form functional circuits and led to measurable improvements in cognitive behavior.
Key Facts
- Mechanistic bypass strategy: The study demonstrates that some neurodevelopmental disorders caused by chromosomal deletions can be treated by activating secondary, compensatory gene networks rather than by restoring expression of the deleted genes themselves.
- Mitochondrial oxidative stress: Elevated reactive oxygen species and mitochondrial dysfunction were identified as key drivers of impaired dendritic branching and disrupted circuit formation in the 22q11.2 deletion model.
- Efficacy of N‑acetyl cysteine (NAC): Systemic NAC treatment reduced oxidative burden, improved mitochondrial health, promoted dendritic growth, and enhanced synaptic signal transmission.
- Behavioral circuit recovery: Strengthening remaining synaptic connections after NAC treatment restored cumulative circuit signaling and produced measurable improvements on behavioral tasks that evaluate learning and cognitive flexibility.
- Clinical translation potential: 22q11.2 deletion syndrome occurs in roughly 1 in 2,000 to 4,000 live births. This compensatory gene-network approach offers a new paradigm for treating complex microdeletion syndromes where direct gene correction is currently difficult.
Source: Virginia Tech
Researchers at the Fralin Biomedical Research Institute at VTC have found how an experimental antioxidant therapy helps vulnerable neurons develop and connect properly despite a disease-causing genetic deletion. Rather than repairing the deletion itself, the treatment redirects cellular development by reducing oxidative damage and activating alternative gene programs that support normal neural circuit formation.
Published in Disease Models & Mechanisms, the findings indicate that for some genetic brain disorders it may be more effective to target disrupted cellular mechanisms — such as mitochondrial oxidative stress — than to attempt direct correction of the underlying DNA change.
The study concentrated on 22q11.2 deletion syndrome, a relatively common chromosomal microdeletion that is among the strongest known genetic risk factors for schizophrenia and is also linked to autism spectrum disorder, developmental delays, and cognitive challenges.
In the mouse model, researchers traced developmental abnormalities in upper-layer cortical projection neurons to increased oxidative stress within mitochondria. This oxidative burden impaired dendritic branching, a critical step for forming synaptic connections and healthy neural circuits.
Treating animals with N‑acetyl cysteine reduced mitochondrial oxidative stress and restored mitochondrial function. As a result, dendrites grew more robustly, synaptic connections strengthened, and the overall integrity of cortical circuits improved.
“Think of it like taking a detour around a blocked roadway,” said Anthony‑Samuel LaMantia, professor at the Fralin Biomedical Research Institute and corresponding author. “The original route remains closed, but an alternate path lets you reach the same destination. NAC activates a different group of genes that enable neurons to build functional circuits despite the genetic deletion.”
Crucially, the researchers found that NAC did not simply restore the expression levels of genes lost or reduced by the 22q11.2 deletion. Instead, the therapy induced distinct transcriptional changes: a mix of genes broadly responsive to NAC and genes that responded specifically in the context of the deletion. These compensatory gene programs supported neuronal growth and antioxidant defenses, producing a unique in vivo transcriptome signature associated with improved circuit development.
Functionally, the treatment did not replace missing neurons; it strengthened the synapses among the neurons that remained. That reinforcement restored the combined signaling strength of circuits underlying learning and cognitive flexibility, and the treated mice showed improved performance on behavioral tasks that rely on those circuits.
While translating these results into human treatments will require more research and clinical testing, the study suggests a promising alternative route for therapies: harnessing the flexibility of gene networks and cellular responses rather than attempting to correct every disrupted gene or pathway directly.
“Gene networks are remarkably adaptable,” LaMantia said. “Therapies that engage that adaptability could be a feasible way to treat complex genetic brain disorders when direct genetic repair is not practical.”
The research team included Anthony‑Samuel LaMantia, Shah Rukh, Daniel Meechan, Abra Roberts, Connor Siggins, Zachary Erwin, and Thomas Maynard from the Fralin Biomedical Research Institute. LaMantia also holds a professorship in the Department of Biological Sciences.
Key Questions Answered:
A: 22q11.2 deletion syndrome is a genetic disorder caused by a missing segment of chromosome 22, occurring in about 1 in 2,000 to 4,000 births. It is one of the strongest known genetic risk factors for schizophrenia and is commonly associated with autism spectrum disorder and developmental delays.
A: NAC reduces mitochondrial oxidative stress by replenishing antioxidant capacity and lowering reactive oxygen species. Rather than reactivating deleted genes, NAC initiates alternative gene programs that support dendritic growth, enhance synaptic connectivity, and restore neural circuit function.
A: Traditional therapies often aim to restore mutated or missing genes to normal expression. This study shows that engaging secondary, naturally flexible gene networks can produce similar structural and behavioral recovery without directly repairing the primary genetic defect, opening a new therapeutic avenue for complex genetic disorders.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by editorial staff.
- Additional background and context were provided by the newsroom team.
About this genetics and neurodevelopment research news
Author: John Pastor
Source: Virginia Tech
Contact: John Pastor – Virginia Tech
Image: The image is credited to Neuroscience News
Original Research: Open access. “An antioxidant therapy elicits distinct transcriptome responses in 22q11‑deleted upper layer cortical projection neurons” by Shah Rukh, Daniel W. Meechan, Abra Roberts, Connor Siggins, Zachary D. Erwin, Thomas M. Maynard, Anthony‑S. LaMantia. Disease Models & Mechanisms. DOI:10.1242/dmm.052786
Abstract
An antioxidant therapy elicits distinct transcriptome responses in 22q11‑deleted upper layer cortical projection neurons
The authors characterized in vitro and in vivo responses to the antioxidant N‑acetyl cysteine (NAC) in the 22q11.2 deletion (LgDel) mouse model. NAC restores growth and connectivity of developing upper-layer cortical projection neurons (Layer 2/3 PNs) and improves cognitive performance in LgDel mice.
NAC reduces developmental pathology in Layer 2/3 PNs without returning growth patterns or downstream gene expression to wild-type levels. Instead, NAC induces expression of novel neuronal growth and antioxidant defense genes that are differentially regulated compared to both LgDel and wild type: some genes are generally responsive to NAC, while others respond only in the context of the 22q11 deletion.
In postnatal LgDel cortex, NAC elicits distinct in vivo changes in differentiating Layer 2/3 projection neurons rather than restoring 22q11 downstream targets to wild-type levels; these in vivo transcriptional responses differ markedly from those observed in primary cell culture. Thus, the therapeutic response that reduces oxidative stress–related developmental, circuit, and behavioral pathology in 22q11 deletion has a distinct in vivo transcriptomic signature.